166 related articles for article (PubMed ID: 20415895)
21. Belatacept utilization recommendations: an expert position.
Grinyó JM; Budde K; Citterio F; Charpentier B
Expert Opin Drug Saf; 2013 Jan; 12(1):111-22. PubMed ID: 23206310
[TBL] [Abstract][Full Text] [Related]
22. Belatacept.
Vincenti F; Dritselis A; Kirkpatrick P
Nat Rev Drug Discov; 2011 Aug; 10(9):655-6. PubMed ID: 21878974
[No Abstract] [Full Text] [Related]
23. Belatacept in kidney transplantation.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2012 Dec; 17(6):640-7. PubMed ID: 23044530
[TBL] [Abstract][Full Text] [Related]
24. Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation.
Zhang H; Wang Z; Zhang J; Gui Z; Han Z; Tao J; Chen H; Sun L; Fei S; Yang H; Tan R; Chandraker A; Gu M
Front Immunol; 2021; 12():618737. PubMed ID: 33732243
[TBL] [Abstract][Full Text] [Related]
25. Belatacept in clinical and experimental transplantation - progress and promise.
Rangel EB
Drugs Today (Barc); 2010 Apr; 46(4):235-42. PubMed ID: 20502720
[TBL] [Abstract][Full Text] [Related]
26. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
[TBL] [Abstract][Full Text] [Related]
27. Are calcineurin inhibitors-free regimens ready for prime time?
Vincenti F
Kidney Int; 2012 Nov; 82(10):1054-60. PubMed ID: 22622502
[TBL] [Abstract][Full Text] [Related]
28. Costimulation targeting therapies in organ transplantation.
Gandhi AM; Fazli U; Rodina V; Qazi YA
Curr Opin Organ Transplant; 2008 Dec; 13(6):622-6. PubMed ID: 19060553
[TBL] [Abstract][Full Text] [Related]
29. Kidney transplant recipients treated with belatacept exhibit increased naïve and transitional B cells.
Leibler C; Matignon M; Pilon C; Montespan F; Bigot J; Lang P; Carosella ED; Cohen J; Rouas-Freiss N; Grimbert P; Menier C
Am J Transplant; 2014 May; 14(5):1173-82. PubMed ID: 24730563
[TBL] [Abstract][Full Text] [Related]
30. Use of belatacept in kidney transplantation: what's new?
Yakubu I; Moinuddin I; Gupta G
Curr Opin Organ Transplant; 2023 Feb; 28(1):36-45. PubMed ID: 36326538
[TBL] [Abstract][Full Text] [Related]
31. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients.
Vincenti F; Larsen CP; Alberu J; Bresnahan B; Garcia VD; Kothari J; Lang P; Urrea EM; Massari P; Mondragon-Ramirez G; Reyes-Acevedo R; Rice K; Rostaing L; Steinberg S; Xing J; Agarwal M; Harler MB; Charpentier B
Am J Transplant; 2012 Jan; 12(1):210-7. PubMed ID: 21992533
[TBL] [Abstract][Full Text] [Related]
32. Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.
Bray RA; Gebel HM; Townsend R; Roberts ME; Polinsky M; Yang L; Meier-Kriesche HU; Larsen CP
Am J Transplant; 2018 Jul; 18(7):1774-1782. PubMed ID: 29573335
[TBL] [Abstract][Full Text] [Related]
33. Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2-year results from the long-term extension of a phase II study.
Grinyo J; Alberu J; Contieri FL; Manfro RC; Mondragon G; Nainan G; Rial Mdel C; Steinberg S; Vincenti F; Dong Y; Thomas D; Kamar N
Transpl Int; 2012 Oct; 25(10):1059-64. PubMed ID: 22816557
[TBL] [Abstract][Full Text] [Related]
34. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion.
Lo DJ; Anderson DJ; Weaver TA; Leopardi F; Song M; Farris AB; Strobert EA; Jenkins J; Turgeon NA; Mehta AK; Larsen CP; Kirk AD
Am J Transplant; 2013 Feb; 13(2):320-8. PubMed ID: 23311611
[TBL] [Abstract][Full Text] [Related]
35. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
[TBL] [Abstract][Full Text] [Related]
36. Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4α senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A.
Furuzawa-Carballeda J; Lima G; Alberú J; Palafox D; Uribe-Uribe N; Morales-Buenrostro LE; Reyes Acevedo R; Mondragón G; Chevaile A; Llorente L
Clin Exp Immunol; 2012 Feb; 167(2):330-7. PubMed ID: 22236010
[TBL] [Abstract][Full Text] [Related]
37. Switch from calcineurin inhibitors to belatacept in kidney transplant patients with chronic-active antibody mediated rejection results in lower decline in kidney function at three years.
de Nattes T; François A; Candon S; Etienne I; Laurent C; Matignon M; Morel A; Noble J; Planchais M; Guerrot D; Bertrand D
J Nephrol; 2021 Dec; 34(6):2159-2162. PubMed ID: 34181198
[No Abstract] [Full Text] [Related]
38. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.
Rostaing L; Vincenti F; Grinyó J; Rice KM; Bresnahan B; Steinberg S; Gang S; Gaite LE; Moal MC; Mondragón-Ramirez GA; Kothari J; Pupim L; Larsen CP
Am J Transplant; 2013 Nov; 13(11):2875-83. PubMed ID: 24047110
[TBL] [Abstract][Full Text] [Related]
39. Transplantation: BENEFIT of belatacept: kidney transplantation moves forward.
Naesens M; Thaunat O
Nat Rev Nephrol; 2016 May; 12(5):261-2. PubMed ID: 27026349
[No Abstract] [Full Text] [Related]
40. Late onset Pneumocystis pneumonia in renal transplantation after long-term immunosuppression with belatacept.
Haidinger M; Hecking M; Memarsadeghi M; Weichhart T; Werzowa J; Hörl WH; Säemann MD
Transpl Infect Dis; 2009 Apr; 11(2):171-4. PubMed ID: 19210692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
